Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.

Wehmeier PM, Schacht A, Ulberstad F, Lehmann M, Schneider-Fresenius C, Lehmkuhl G, Dittmann RW, Banaschewski T.

J Clin Psychopharmacol. 2012 Oct;32(5):653-60.


Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13.


Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.

Wehmeier PM, Schacht A, Dittmann RW, Helsberg K, Schneider-Fresenius C, Lehmann M, Bullinger M, Ravens-Sieberer U.

Qual Life Res. 2011 Jun;20(5):691-702. doi: 10.1007/s11136-010-9803-5. Epub 2010 Dec 7.


Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry.

Yu P, Constien R, Dear N, Katan M, Hanke P, Bunney TD, Kunder S, Quintanilla-Martinez L, Huffstadt U, Schröder A, Jones NP, Peters T, Fuchs H, de Angelis MH, Nehls M, Grosse J, Wabnitz P, Meyer TP, Yasuda K, Schiemann M, Schneider-Fresenius C, Jagla W, Russ A, Popp A, Josephs M, Marquardt A, Laufs J, Schmittwolf C, Wagner H, Pfeffer K, Mudde GC.

Immunity. 2005 Apr;22(4):451-65.


Molecular characterization of glucokinase from Escherichia coli K-12.

Meyer D, Schneider-Fresenius C, Horlacher R, Peist R, Boos W.

J Bacteriol. 1997 Feb;179(4):1298-306.

Supplemental Content

Loading ...
Support Center